Filana Therapeutics, Inc. FLNA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Filana Therapeutics, Inc. (FLNA) is a healthcare company listed in the US with a market value of about $21M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -55%.
About Filana Therapeutics
Filana Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 20% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$91M | -$24M | -$97M | -$76M | -$32M | -$6M | -$5M | -$7M | -$12M | -$15M |
| Free cash flow | -$33M | -$117M | -$82M | -$80M | -$52M | — | -$3M | — | — | -$12M |
| EPS (diluted) | $-1.88 | $-1.46 | $-2.32 | $-1.90 | $-0.82 | $-0.24 | $-0.27 | $-0.61 | $-1.82 | $-2.28 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -101.3% | -76.7% | -60.9% | -27.8% | -10.2% | -5.5% | -17.7% | -26.8% | -97.3% | -63.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $6.50, 1429% above the current price; targets range from $5.00 to $8.00; the consensus rating is “Strong buy”; expected EPS is $-0.86 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Filana Therapeutics pay a dividend?
Not currently.
Is Filana Therapeutics a good stock to buy?
We do not give buy or sell advice. Filana Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.